Imbio RV/LV Software vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Imbio RV/LV Software

by Imbio

EchoNext

by Pathway Labs

AI Verdict

Both tools leverage AI in cardiology and are FDA-cleared, but they operate on different diagnostic inputs and target slightly different stages of patient assessment. Imbio RV/LV Software focuses on analyzing CTPA scans to assess ventricular dimensions for pulmonary conditions, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, the choice depends on whether the need is for CTPA-based ventricular assessment or ECG-based structural heart disease screening.

Choose Imbio RV/LV Software if…

Choose Imbio RV/LV Software if your primary need is automated, quantitative analysis of right and left ventricular diameters from CTPA scans to aid in risk stratification for pulmonary conditions like pulmonary embolism. This tool is ideal for radiologists and pulmonologists who require rapid, consistent assessment of potential right heart strain and want to integrate these measurements directly into their existing PACS workflow.

View Imbio RV/LV Software →

Choose EchoNext if…

Choose EchoNext if you need an AI-powered screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard 12-lead ECGs. This tool is best suited for broad clinical settings, from major hospitals to community practices, looking for an affordable and non-invasive method to identify patients who should undergo further evaluation with echocardiography.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Imbio RV/LV Software	EchoNext
Pricing	Subscription-based	Starts at $600/month
Deployment	Cloud-based (Imbio Cloud in AWS with Imbio Bridge), on-premise (Imbio Enterprise as a software-only VMware solution), or via partner platforms (e.g., Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Imbio RV/LV Software

Imbio RV/LV Software is designed for a fully automated workflow, integrating directly with PACS and delivering results without user intervention or the need for new interfaces. EchoNext, while accessible through a clinical decision support platform, still requires clinicians to interpret ECG data and determine the need for follow-up, suggesting a less seamless integration into existing workflows.

Clinical Value

EchoNext

EchoNext demonstrates higher clinical value by detecting a broader range of hidden structural heart diseases from routine ECGs with superior accuracy compared to cardiologists, and has shown to identify thousands of undiagnosed cases. Imbio RV/LV Software provides automated measurements for risk stratification in pulmonary conditions like pulmonary embolism, which is valuable but more narrowly focused.

Pricing & Value

EchoNext

EchoNext offers tiered pricing with clear monthly costs and potential annual discounts, providing transparency and flexibility for different institutional sizes. Imbio RV/LV Software's pricing is subscription-based, dependent on the number of analyses and installations, which is less transparent without direct inquiry. While both offer value, EchoNext's upfront pricing structure makes it easier for potential buyers to assess the financial commitment.

Enterprise Readiness

Imbio RV/LV Software

Imbio RV/LV Software offers flexible deployment options including cloud-based, on-premise, or via numerous partner platforms, indicating robust enterprise readiness and adaptability to various IT infrastructures. EchoNext is available through a single clinical decision support platform, which, while widely used, suggests a more limited deployment ecosystem.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a test traditionally not used for this purpose. This expands the diagnostic potential of a common, inexpensive test. Imbio RV/LV Software automates existing measurements from CTPA scans, which is valuable for efficiency but less groundbreaking in its diagnostic approach.

Support & Docs

Tie

Both tools are FDA-cleared and HIPAA compliant, implying a baseline level of documentation and adherence to regulatory standards. However, specific details regarding the depth and accessibility of user support, training materials, and comprehensive documentation beyond regulatory compliance are not explicitly provided for either tool in the given information or readily available through web searches. Therefore, it is difficult to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Imbio RV/LV Software	EchoNext
Tool Name	Imbio RV/LV Software	EchoNext
Company	Imbio	Pathway Labs
Description	AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Input	CTPA scans	Standard 12-lead ECGs
Primary Output/Function	Automated measurement of right and left ventricular diameters, calculation and reporting of RV/LV ratio, annotated images, summary PDF reports.	Detection of hidden structural heart disease, identifies heart failure risk, screens for valve disease, detects pulmonary hypertension indicators.
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Imbio RV/LV Software and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into my existing cardiology or radiology workflow, and what is the expected learning curve for my team?

Imbio RV/LV Software is designed for a fully automated workflow, requiring no user intervention after scan completion and integrating with standard reading environments (PACS). This suggests a minimal learning curve for radiologists. EchoNext, on the other hand, analyzes standard ECGs and is available through the OpenEvidence clinical decision support platform. The learning curve for EchoNext would likely involve understanding the interpretation of its AI-powered ECG analysis within the clinical decision support framework.

Given their distinct focuses, how do the accuracy and sensitivity of Imbio RV/LV Software for ventricular measurements compare to EchoNext's ability to detect hidden structural heart disease from ECGs?

Imbio RV/LV Software automatically measures right and left ventricular diameters from CTPA scans and calculates the RV/LV ratio to aid in risk stratification for pulmonary conditions. EchoNext utilizes AI-powered ECG analysis to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension indicators. While both are FDA-cleared, their accuracy and sensitivity metrics would be specific to their respective diagnostic tasks and input modalities (CTPA vs. ECG).

What kind of support can I expect during implementation and ongoing use for both Imbio RV/LV Software and EchoNext, and what is the typical time-to-value?

Imbio RV/LV Software offers deployment flexibility, including cloud-based, on-premise, or via partner platforms, which may influence implementation support. EchoNext has a 10% implementation & onboarding fee for most plans, suggesting structured support during initial setup. The time-to-value for Imbio RV/LV, with its fully automated workflow, could be relatively quick once integrated into PACS. For EchoNext, the time-to-value would depend on how quickly clinicians adopt and integrate its ECG analysis into their diagnostic pathways.

Can I access customer references or case studies to understand real-world experiences and outcomes with Imbio RV/LV Software and EchoNext?

The provided information does not explicitly state the availability of customer references or case studies for either Imbio RV/LV Software or EchoNext. However, given their FDA clearance and stated applications in clinical settings, it would be reasonable for a physician to inquire directly with Imbio and Pathway Labs for such resources to evaluate real-world performance and user satisfaction.

What audit-trail features do these tools offer to ensure transparency and accountability in their AI-driven analyses?

Imbio RV/LV Software generates summary PDF reports and provides annotated images showing ventricular measurements, which could contribute to an audit trail of its analysis. The description for EchoNext focuses on its AI-powered ECG analysis and detection capabilities. For both tools, understanding the specific audit-trail features, such as logging of AI decisions, user interactions, and data access, would be crucial for clinical governance and accountability.

How do these tools support multi-site rollout, and what considerations should be made for consistent implementation and performance across different clinical environments?

Imbio RV/LV Software offers flexible deployment options, including cloud-based, on-premise, or via partner platforms, which could facilitate multi-site rollouts depending on the chosen model. EchoNext is available through the OpenEvidence clinical decision support platform, suggesting a potentially standardized deployment across sites utilizing that platform. For both, considerations for consistent implementation would include standardized training, integration with diverse PACS or EHR systems, and ensuring consistent performance of the AI algorithms across different patient populations and imaging/ECG equipment.